IL6 and neoplasm: Biomarker analyses of HCC patients treated with sunitinib showed a correlation between decreased levels of IL-6 and soluble c-KIT and a delayed tumor progression; vice versa elevated levels of IL-6 and c-KIT were associated with an unfavorable disease course [92].